ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Provention Bio Begins Phase 2 Study of Non-responsive Celiac Disease Treatment
September 01, 2020Provention Bio announced the initiation of the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as ...
Pharma Sources Insight January 2025
